“Untreatable” cases of cystic fibrosis may be undermined by new therapy
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
List view / Grid view
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
A non-invasive, label-free optical method can produce high-resolution imaging of cellular brain diseases in vivo.
A US team has designed a high-quality, high-speed imaging system that could lead to new understandings of complex tissue specimens.
A team have developed a minimally invasive exosome spray that helped repair rat hearts after myocardial infarction.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
Researchers have published a step-by-step protocol on how to produce millions of mature human cells in a chimeric mouse embryo.
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
In non-human primates, researchers have found that mesenchymal stem cells were effective at strengthening the immune response to HIV.
A new mRNA-based vaccine has demonstrated success at protecting against multiple coronaviruses in pre-clinical studies.
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.